Biogen Stock Forecast for 2023 - 2025 - 2030
Updated on 03/29/2024
Biogen Stock Forecast and Price Target
Given the average yearlong price target of $297.00 provided by thridteen prominent analysts over the past few months, there is a potential upside of approximately 29.09% from the last closing price in March, 2024 for Biogen's stock if it is reached. This estimation is based on a high estimate of $400.00 and a low estimate of $230.00. If you're interested in investing in this company, why not also look at its competitors to see how they are doing?
29.09% Upside
Biogen Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Biogen's Price has decreased from $423.95 to $0.00 – a 100.00% drop. In the next year, analysts predict that Fair Value will reach $211.60 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$734.37 | Buy/Sell | $636.99 | 10.71% |
NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
12
|
kr895.10 | Buy/Sell | kr696.07 | 6.13% |
JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$161.23 | Buy/Sell | $174.55 | 5.44% |
ABBV Stock Forecast | AbbVie | Outperform |
9
|
$179.63 | Buy/Sell | $178.42 | 0.21% |
MRK Stock Forecast | Merck | Outperform |
2
|
$122.77 | Buy/Sell | $130.51 | 9.96% |
Biogen Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Biogen's Revenue has decreased from $13.44B to $9.84B – a 26.84% drop. For the following year, the 26 analysts predict that Biogen's Revenue will drop by 3.82%, reaching $9.46B. For the next seven years, the forecast is for Revenue to grow by 8.44%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF242.00 | Buy/Sell | CHF307.83 | 11.57% |
AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£104.50 | Buy/Sell | £165.99 | 53.79% |
NOVN Stock Forecast | Novartis | Outperform |
10
|
CHF88.80 | Buy/Sell | CHF105.00 | 23.95% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
DHR Stock Forecast | Danaher | Outperform |
10
|
$252.80 | Buy/Sell | $260.33 | 2.85% |
PFE Stock Forecast | Pfizer | Outperform |
2
|
$28.37 | Buy/Sell | $32.87 | 10.82% |
AMGN Stock Forecast | Amgen | Outperform |
4
|
$275.36 | Buy/Sell | $303.65 | 14.40% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
SAN Stock Forecast | Sanofi | Outperform |
16
|
88.32€ | Buy/Sell | 102.80€ | 21.15% |
MDT Stock Forecast | Medtronic | Outperform |
11
|
$85.50 | Buy/Sell | $92.47 | 11.11% |
BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$54.36 | Buy/Sell | $58.15 | 1.18% |
Biogen EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Biogen has seen a decline in its EBITDA, from $5.11B to $2.38B – a 53.51% decrease. In the next year, analysts expect EBITDA to reach $3.83B – an increase of 61.13%. For the next seven years, the forecast is for EBITDA to grow by 53.22%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
12
|
$414.47 | Buy/Sell | $457.59 | 8.57% |
REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$964.44 | Buy/Sell | $961.26 | 8.87% |
GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$75.32 | Buy/Sell | $87.82 | 10.20% |
Biogen EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Biogen's EBIT has decreased by 59.57%, from $4.66B to $1.88B. The next year looks promising for Biogen, with analysts predicting EBIT of $2.94B – an increase of 56.08%. Over the next seven years, experts anticipate that Biogen's EBIT will grow at a rate of 71.28%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
CSL Stock Forecast | CSL | Outperform |
12
|
$281.20 | Buy/Sell | $205.51 | -27.94% |
GSK Stock Forecast | GSK | Outperform |
12
|
£16.75 | Buy/Sell | £17.30 | 11.04% |
ZTS Stock Forecast | Zoetis | Outperform |
18
|
$183.49 | Buy/Sell | $220.47 | 20.72% |
Biogen EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Biogen's EPS has decreased from $33.70 to $0.00 – a 100.00% drop. In the next year, analysts predict that EPS will reach $16.82 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
MRK Stock Forecast | Merck KGaA | Outperform |
18
|
156.75€ | Buy/Sell | 190.06€ | 9.73% |
4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.31k | Buy/Sell | ¥4.74k | 6.63% |
MRNA Stock Forecast | Moderna | Outperform |
16
|
$111.98 | Buy/Sell | $135.42 | 11.09% |